Abstracts of the 2023 Annual Meeting of the ALEH
More infoNo
Introduction and ObjectivesInflammatory bowel disease (IBD) is a globally increasing condition. There is growing interest in the comorbidities associated with IBD, including steatotic liver disease (SLD). SLD has been demonstrated in individuals with IBD, even in the absence of other metabolic factors. Few studies have evaluated this association in the Latin American population. Objectives: The study aims to evaluate the frequency of SLD in Chilean subjects with IBD and its association with clinical and metabolic variables.
Patients / Materials and MethodsWe conducted a retrospective cross-sectional study of 148 adults with IBD (Crohn's disease: 89, ulcerative colitis: 46, and unclassified colitis: 13) who had abdominal imaging such as ultrasound, CT, or MRI in the last 15 years. Patients were considered to have SLD if this diagnosis was reported in the imaging report. Differences between groups were evaluated using chi-square and non-parametric tests.
Results and DiscussionThe median age of this cohort was 48 years (Q1: 37, Q3: 63 years), and 85 (57.4%) were female. Thirty patients (20.2%) had SLD. Subjects with SLD had significantly higher weight (75.8 vs 66kg, p<0.001) and body mass index (27.6 vs 22.6kg/m², p<0.001) compared with subjects without SLD. In multivariate analysis, this association remained significant independently of age, sex, and IBD disease activity (p<0.001). The use of corticosteroids showed a 100% association with SLD (p<0.001). No significant association was observed between SLD and other treatments or variables such as age, sex, type or activity of IBD, gallstones, triglyceridemia, glucose, or smoking.
ConclusionsThe frequency of SLD in Chilean patients with IBD is within the lower range of previous reports in other series. In our sample, the variables associated with SLD in subjects with IBD were elevated BMI and corticosteroid therapy.
